Double-blind trial evaluates pramipexole augmentation in unipolar treatment-resistant depression, suggesting efficacy.
The oral nonergot dopamine agonist pramipexole (Mirapex ER, and generics), which is FDA-approved for treatment of Parkinson's disease and restless legs syndrome, has been used off-label in patients with treatment-resistant depression (TRD).1 A double-blind, placebo-controlled trial of pramipexole augmentation in patients with unipolar TRD was recently published.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: